The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study.

Autor:	Francini E; Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy. Electronic address: edoardo.francini@unifi.it., Ou FS; Mayo Clinic, Rochester, MN, USA., Lazzi S; Department of Human Pathology and Oncology, University of Siena, Siena, Italy., Petrioli R; Santa Maria Alle Scotte Hospital, Siena, Italy., Multari AG; Santa Maria Alle Scotte Hospital, Siena, Italy., Pesola G; Santa Maria Alle Scotte Hospital, Siena, Italy., Messuti L; Santa Maria Alle Scotte Hospital, Siena, Italy., Colombo E; Santa Maria Alle Scotte Hospital, Siena, Italy., Livellara V; Santa Maria Alle Scotte Hospital, Siena, Italy., Bazzurri S; Santa Maria Alle Scotte Hospital, Siena, Italy., Cherri S; Santa Maria Alle Scotte Hospital, Siena, Italy., Miano ST; Santa Maria Alle Scotte Hospital, Siena, Italy., Wolfe EG; Mayo Clinic, Rochester, MN, USA., Alberts SR; Mayo Clinic, Rochester, MN, USA., Hubbard JM; Mayo Clinic, Rochester, MN, USA., Yoon HH; Mayo Clinic, Rochester, MN, USA., Francini G; Department of Medical and Surgical Sciences and Neuroscience, University of Siena, Siena, Italy.
Jazyk:	angličtina
Zdroj:	Translational oncology [Transl Oncol] 2021 Feb; Vol. 14 (2), pp. 100973. Date of Electronic Publication: 2020 Dec 15.
DOI:	10.1016/j.tranon.2020.100973
Abstrakt:	Background: High tumor infiltrating lymphocytes (TILs) density was previously shown to be associated with favorable prognosis for patients with colon cancer (CC). However, the impact of TILs on overall survival (OS) of stage II CC patients who received adjuvant chemotherapy (ADJ) or not (no-ADJ) is unknown. We assessed the prognostic value of CD3+ TILs in stage II CC patients according to whether they had ADJ or not. Methods: Patients treated with curative surgery for stage II CC (2002-2013) were selected from the Santa Maria alle Scotte Hospital registry. TILs at the invasive front, center of tumor, and stroma were determined by immunohistochemistry and manually quantified as the rate of TILs/total tissue areas. High TILs (H-TILs) was defined as >20%. Patients were categorized as high or low TILs (L-TILs) and ADJ or no-ADJ. Results: Of the 678 patients included, 137 (20%) received ADJ and 541 (80%) did not. The distribution of the 4 groups were: 16% (L-TIL/ADJ), 64% (L-TIL/no-ADJ), 5% (H-TIL/ADJ), 15% (H-TIL/no-ADJ). Compared to H-TILs/no-ADJ, ADJ patients showed a significantly increased OS (P<.01) regardless of the TILs rate whereas L-TILs/no-ADJ had significantly decreased OS and higher risk of death (HR=1.41; 95% CI, 1.06-1.88; P<.0001). On multivariable analysis, the unfavorable prognostic value of L-TILs (vs. H-TILs) for no-ADJ patients was confirmed (HR=1.36; 95% CI 1.02, 1.82; P=.0373). Conclusion: Low CD3+ TILs rate was associated with shorter OS in those with stage II colon cancer who did not receive adjuvant therapy. Low CD3+ TILs could be considered an additional risk factor for still ADJ-untreated stage II CC patients, which could facilitate clinical decision making. Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu